Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1; 2ГБОУ ВПО Самарский государственный медицинский университет Минздрава России. 443099, Россия, Самара, ул. Чапаевская, д. 89
Список исп. литературыСкрыть список 1. Краснов В.Н. Расстройства аффективного спектра. М.: Практическая медицина, 2011; с. 114–37. / Krasnov V.N. Rasstroistva affektivnogo spektra. M.: Prakticheskaia meditsina, 2011; s. 114–37. [in Russian] 2. Павличенко А.В., Овсепян А.А. Современные стратегии лечения аффективных расстройств: обзор материалов 26-го Конгресса Европейской коллегии нейропсихофармакологии. Психиатрия и психофармакотерапия. 2014; 16 (4): 19–25. / Pavlichenko A.V., Hovsepyan A.A. Modern treatment strategies of affective disorders: review of the materials of the 26st European College of Neuropsychopharmacology. Psychiatry and Psychopharmacotherapy. 2014; 16 (4): 19–25. [in Russian] 3. Andreazza AC еt al. 3-Nitrotyrosine glutathione antioxidant system in patients in the early late stages of bipolar disorder. J Psychiatry Neurosci 2009; 34: 263–71. 4. Azorin JM et al. Correlates of first-episode polarity in a French cohort of 1089 bipolar I disorder patients: role of temperaments and triggering events. J Affect Disord 2011; 129: 39–46. 5. BALANCE investigators and collaborators. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375: 385–95. 6. Balanza-Martinez V et al. Persistent cognitive dysfunctions in bipolar I disorder and schizophrenic patients: a 3-year follow-up study. Psychother Psychosom 2005; 74: 113–9. 7. Bechdolf A et al. Amygdala and insula volumes prior to illness onset in bipolar disorder: a magnetic resonance imaging study. Psychiatry Res 2012; 201: 34–9. 8. Berk M et al. The potential utility of a staging model as a course specifier: a bipolar disorder perspective. J Affect Disord 2007; 100: 279–81. 9. Berk M et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804–17. 10. Berk M et al. Palliative models of care for later stages of mental disorder: maximizing recovery, maintaining hope, and building morale. Aust N Z J Psychiatry 2012; 46: 92–9. 11. Bonnin CMA et al. Subthreshold symptoms in bipolar disorder: impact on neurocognition, quality of life and disability. J Affect Disord 2011; 136: 650–9. 12. Bourne C, Aydemir O Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand 2013; 128: 149–62. 13. Canales-Rodriguez EJ et al. Structural abnormalities in bipolar euthymia: A Multicontrast Molecular Diffusion Imaging Study. Biol Psychiatry 2013. 14. Chen CH, Lee CS et al. Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med 2014; 370 (2): 119–28. 15. Cosci F, Fava GA. Staging of mental disorders: systematic review. Psychother Psychosom 2013; 82: 20–34. 16. Dias VV et al. Cognitive function and serum levels of brain derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord 2009; 11: 663–71. 17. Fava GA, Kellner R. Staging: a neglected dimension in psychiatric classification. Acta Psychiatr Scand 1993; 87: 225–30. 18 Fernandes BS et al. Brain-derived neurotrophic in mania, depression, and euthymia in bipolar disorders: a systematic review and meta-analysis. Bipolar Disord 2010; 12: 19. 19. Forcada I. The influence of cognitive reserve on psychosocial and neuropsychological functioning in bipolar disorder. Eur Neuropsychopharmacol 2014. 20. Insel T.R. Transforming Diagnosis 2013. htpp://www. nimh.nih.gov/about/director/2013/transforming-diagnosis.shtml 21. Gelenberg AJ et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321: 1489–93. 22. Ghaemi SN et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of longterm effectiveness and safety. J Clin Psychiatry 2010; 71: 372–80. 23. Goodwin GM, Geddes JR. What is the heartland of psychiatry? Br J Psychiatry 2007; 191: 189–91. 24. Goodwin FK. Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment. J Clin Psychiatry 2002; 63 (Suppl. 10): 5–12. 25. Goodwin GM, Martinez-Aran A. Cognitive impairment in bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert meeting report. Eur Neuropsychopharmacol 2008; 18: 787–93. 26. Hickie IB et al. Clinical classification in mental health at the cross-roads: which direction next? BMC Med 2013; 11: 125. 27. Javadapour A et al. Increased anterior cingulate cortex volume in bipolar I disorder. Aust N Z J Psychiatry 2007; 41: 910–6. 28. Jonsdottir H et al. Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatr Scand 2013; 127: 23–33. 29. Kapczinski F et al. Clinical implications of a staging model for bipolar disorders. Expert Rev Neurother 2009; 9: 957–66. 30. Kapczinski FA. Systemic toxicity index developed to assess peripheral changes in mood episodes. Mol Psychiatry 2010; 15 (8): 784–6. 31. Kapczinski F et al. Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report. Acta Psychiatr Scand 2014; p. 1–10. 32. Kerner B. Genetics of bipolar disorder. The Application of Clinical Genetics 2014; 7: 33–42. 33. Kim P et al. Differing amygdala responses to facial expressions in children and adults with bipolar disorder. Am J Psychiatry 2012; 169: 642–9. 34. Lim CS, Baldessarini RJ et al. Longitudinal neuroimaging and neuropsychological changes in bipolar disorder patients: review of the evidence. Neurosci Biobehav Rev 2013; 37: 418–35. 35. Lopez-Jaramillo C et al. Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. Bipolar Disord 2010; 12: 557–67. 36. Lopez-Munoz F, Vieta E et al. Bipolar disorder as an emerging pathology in the scientific literature: a bibliometric approach. J Affect Disord 2006; 92: 161–70. 37. Magalhaes PV et al. Cumulative morbidity and prognostic staging of illness in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Aust N Z J Psychiatry 2012; 46: 1058–67. 38. Magalhaes PV, Dean OM, Bush AI et al. Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2012b; 37: 132–5. 39. Mancia M, Mazda A. Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. PLoS One 2013; 8 (6): e65636. 40. Martinez-Aran A et al. Do cognitive complaints in euthymic bipolar patients reflect objective cognitive impairment? Psychother Psychosom 2005; 74: 295–302. 41. Martinez-Aran A et al. Functional Remediation for Bipolar Disorder. Clin Pract Epidemiol Ment Health 2011; 7: 112–6. 42. McGorry PD et al. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 2006; 40: 616–22. 43. Merikangas K. Independence of familial transmission of mania and depression: results of the NIMH family study of affective spectrum disorders. Molecular Psychiatry 2013; 10. 44. Mur M et al Persistent neuropsychological deficit in euthymic bipolar patients: executive function as a core deficit. J Clin Psychiatry 2007; 68: 1078–86. 45. Nivoli AM et al. Treatment strategies according to clinical features in a naturalistic cohort study of bipolar patients: a principal component analysis of lifetime pharmacological and biophysic treatment options. Eur Neuropsychopharmacol 2013; 23: 263–75. 46. Papachristou E et al. Child Behavior Checklist-Mania Scale (CBCL-MS): development and evaluation of a population-based screening scale for bipolar disorder. PLoS One 2013; 8 (8): e69459. 47. Papachristou E et al. Expanding conceptual frameworks: life course risk modelling for mental disorders. Psychiatry Res 2013; 206 (2–3): 140–5. 48. Pomarol-Clotet E et al. Failure of deactivation in the medial frontal cortex in mania: evidence for default mode network dysfunction in the disorder. World J Biol Psychiatry 2012; 13: 616–26. 49. Popovic D et al. Polarity index of psychological interventions in maintenance treatment of bipolar disorder. Psychother Psychosom 2013; 82: 292–8. 50. Post RM et al. Neurobiological correlates of illness progression in the recurrent affective disorders. J Psychiatr Res 2012; 46: 561–73. 51. Price FS, Morris JA. The genetics of bipolar disorder. BMJ 2013; 346: 1530. 52. Reinares M et al. The impact of staging bipolar disorder on treatment outcome of family psychoeducation. J Affect Disord 2010; 123: 81–6. 53. Reinares M et al. Towards a clinical staging for bipolar disorder: defining patient subtypes based on functional outcome. J Affect Disord 2013; 144: 65–71. 54. Rosa AR et al. One year psychosocial functioning in patients in the early vs. late stage of bipolar disorder. Acta Psychiatr Scand 2012; 125: 335–41. 55. Ruhe HG et al. Staging methods for treatment resistant depression. A systematic review. J Affect Disord 2011; 137: 35–45. 56. Schumann G, Binder E et al. Stratified medicine for mental disorders. Eur Neuropsychopharmacol 2014; 24: 5–50. 57. Scott J et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders – Randomised controlled trial. Br J Psychiatry 2006; 188: 313–20. 58. Scott J. Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value. Br J Psychiatry 2013; 202 (4): 243–5. 59. Svendsen RP et al. Prevalence of cancer alarm symptoms: a population-based cross-sectional study. Scand J Prim Health Care 2010; 28 (3): 132–7. 60. Tohen M et al. Baseline characteristics and outcomes in patients with first episode or multiple episodes of acute mania. J Clin Psychiatry 2010; 71: 255–61. 61. Torrent C et al. Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. Am J Psychiatry 2013; 170: 852–9. 62. Torres IJ et al. Neurocognitive functioning in patients with bipolar I disorder recently Recovered from a first manic episode. J Clin Psychiatry 2010; 71: 1234–42. 63. Vargas C et al. A systematic literature review of resting state network-functional MRI in bipolar disorder. J Affect Disord 2013; 150: 727–35. 64. Vieta A et al. Gray matter, white matter, brain, and intracranial volumes in first-episode bipolar disorder: a meta-analysis of magnetic resonance imaging studies. Bipolar Disord 2009; 11: 807–14. 65. Vieta E et al. Staging bipolar disorder. Neurotox Res 2011; 19: 279–85. 66. Vieta E. Bipolar Disorder in Clinical Practice. 3rd Ed. CMG London, 2013. 67. Vieta E. The bipolar maze: a roadmap through translational psychopathology. Acta Psychiatr Scand 2014; 129: 323–7. 68. Vieta E, Grunze H et al. Phenomenology of manic episodes according to the presence or absence of depressive features as defined in DSM-5: Results from the IMPACT self-reported online survey. J Affect Disord 2014; 156: 206–13.